Increasing HPV vaccination in HIV positive adults
Implementing an Evidence-Based, Multilevel Intervention to Promote HPV Vaccination Among HIV Positive Adults
This study is testing a program to help healthcare providers in Georgia increase HPV vaccination rates among adults living with HIV to better protect them from HPV-related diseases.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 365 (estimated) |
| Ages | 18 Years to 45 Years |
| Sex | All |
| Sponsor | Emory University Academic / other |
| Locations | 4 sites (Albany, Georgia and 3 other locations) |
| Trial ID | NCT05065840 on ClinicalTrials.gov |
What this trial studies
This study aims to enhance HPV vaccination rates among people living with HIV (PLWH) by implementing the CDC's 4 Pillars Transformation Program in three HIV clinics in Georgia. The program provides evidence-based strategies and training for healthcare providers to improve awareness and uptake of the HPV vaccine, which is crucial for reducing the risk of HPV-related diseases in this high-risk population. The study will involve enrolling providers and clinic staff who will participate in focus groups and training sessions to better understand HPV and vaccination practices. By tailoring the program specifically for PLWH, the study seeks to address significant gaps in vaccination rates and knowledge within this community.
Who should consider this trial
Good fit: Ideal candidates for this study are HIV positive adults aged 18-45 who have not previously received the HPV vaccine.
Not a fit: Patients with contraindications to the HPV vaccine or those who are currently pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this initiative could significantly reduce the incidence of HPV-related diseases among HIV positive adults.
How similar studies have performed: Previous studies have shown success in increasing HPV vaccination rates in the general population using similar evidence-based approaches, making this a promising adaptation for the HIV population.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria * HIV positive * 18-45 years of age * Can read and speak English * Capable of providing informed consent * Has not previously received three series HPV vaccine * No contraindications to receiving HPV vaccine (i.e. history of anaphylactic allergy to later, an immediate hypersensitivity to yeast, current moderate or severe acute illness, and/or are currently pregnant). Exclusion Criteria: * Has contraindications to receiving the HPV vaccine i.e., history of an anaphylactic allergy to latex, an immediate hypersensitivity to yeast, current moderate or severe acute illness, and/or are currently pregnant)
Where this trial is running
Albany, Georgia and 3 other locations
- Albany Rural Model Clinic — Albany, Georgia, United States (Recruiting)
- AID Atlanta — Atlanta, Georgia, United States (Recruiting)
- Faebris — Atlanta, Georgia, United States (Recruiting)
- AHF Lithonia — Lithonia, Georgia, United States (Recruiting)
Study contacts
- Principal investigator: Jessica Wells, PhD, RN — Emory University
- Study coordinator: Jessica Wells, PhD, RN
- Email: jholme3@emory.edu
- Phone: 404-727-0518
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.